Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GAIT Authors Seek Further Study Of Moderate-To-Severe Arthritis Sufferers

This article was originally published in The Tan Sheet

Executive Summary

Authors of the GAIT study have submitted a proposal to further evaluate the effects of glucosamine and chondroitin on osteoarthritis patients by focusing specifically on those with moderate-to-severe pain, according to the study's lead researcher

You may also be interested in...



Study Makes MOVES For Chondroitin/Glucosamine On Osteoarthritis Pain

At six months, 79.7% of the moderate-to-severe patients in the supplementation group and 79.2% in the celecoxib group fulfilled pain reduction criteria, the primary outcome measured in the Multicenter Osteoarthritis InterVEntion trial with SYSADOA.

Study Makes MOVES For Chondroitin/Glucosamine On Osteoarthritis Pain

At six months, 79.7% of the moderate-to-severe patients in the supplementation group and 79.2% in the celecoxib group fulfilled pain reduction criteria, the primary outcome measured in the Multicenter Osteoarthritis InterVEntion trial with SYSADOA.

GAIT II “Conflicts” With Existing Glucosamine/Chondroitin Data, CRN Says

Results of a follow-up glucosamine and chondroitin study measuring loss of knee cartilage in patients with osteoarthritis are inconsistent with the trial's earlier arm

Related Content

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel